Vaccine manufacturing company Pfizer expects demand for the Covid-19 vaccine to increase its revenue for years to come.
According to Pfizer, it expects 'strong demand' for the vaccine, similar to that for the flu vaccine.
In the first three months of this year, the Covid-19 vaccine generated revenue of US $ 3.5 billion after several countries worked to curb the spread of the epidemic.
Revenue from the Covid-19 treatment is expected to reach US $ 26 billion this year, accounting for more than a third of Pfizer's sales.
The projection is based on a contract already signed for 1.6 billion doses of vaccine to be shipped this year.
Pfizer says it will sign more agreements this year and is in talks on vaccine supply with several countries for next year and beyond.
The two -injection vaccine was the best -selling product for Pfizer for the first quarter of this year.
Expenses and profits from the vaccine are shared equally between Pfizer and its German partner BioNTech.
Pfizer is now reportedly testing the use of a third injection of the vaccine as a ‘booster’ and expects the United States (US) to give approval for it to be used on children between the ages of 12 and 15 during a pandemic.
The company is also testing the safety and effectiveness of the vaccine in children between the ages of six months and 11 years.
